| Old Articles: <Older 3071-3080 Newer> |
|---|
 |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue.   |
The Motley Fool
August 16, 2006
S.J. Caplan |
Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
InternetNews
August 10, 2006
Sean Michael Kerner |
Healthcare, Meet Open Source IBM this week said it is open sourcing technology to the Eclipse Foundation's Open Healthcare Framework project in an effort to bridge the information silos. |
BusinessWeek
August 14, 2006
Timothy J. Mullaney |
Massive Buyout, Little Wiggle Room The $33 billion HCA deal will have to work perfectly to work at all. |
BusinessWeek
August 14, 2006
Susan Berfield |
Less Insult From Injury Dan Robinson's ordeal with his son's rare illness led Intuit to develop software to untangle hospital bills. |
BusinessWeek
August 14, 2006
Howard Gleckman |
So That's Why It's So Expensive Blame insurance, not just tech, for spiraling health costs, says an MIT economist. |
Bio-IT World
Jul/Aug 2006
John Russell |
Pharsight CRADA to Assist FDA with Modeling Initiative Pharsight will use FDA's feedback to further develop their server to meet drug-maker's analysis requirements, and further develop their visualization and collaboration tool to support FDA-sponsor interactions for the visualization and communication of model-based product profiles. |
Bio-IT World
Jul/Aug 2006
Michael A. Greeley |
Monsoon of Capital The private equity markets, both venture capital and growth equity, while characterized by a number of established firms, continue to struggle with how best to finance early-stage, risky bio-IT companies. |
Bio-IT World
Jul/Aug 2006
Eric Newmark |
From Inventory to Information Drug safety initiatives, technical innovation, and lean practices are changing the way pharmaceutical supply chains operate. As a result, the role distributors play within that value chain is evolving. |
| <Older 3071-3080 Newer> Return to current articles. |
